Videos

Partho Sengupta, MD, DM, FACC, FASE, Henry Rutgers Professor of Cardiology and Chief of Cardiovascular Medicine, at Robert Wood Johnson Medical School, and Chief of the Cardiovascular Service Line at Robert Wood Johnson University Hospital, offers an overview of the current state of artificial intelligence (AI) in cardiology. He offers insights from what he has seen from some of the more than 160 FDA-cleared algorithms specific to cardiovascular medicine and what is in development.

Exploring the evolution of AI in cardiology

Partho Sengupta, MD, shared his perspective on the current state of artificial intelligence in cardiology. The technology continues to evolve, he said, though it does still face certain limitations.

Raj Kedar, MD, MBBS, FACR, vice chair of radiology and the University of South Florida, and chief of radiology at Tampa General Hospital, discusses how radiology and the hospital planned to continue operations, despite likely being cut off due to flooding and outside power loss during hurricanes Helene and Milton in the fall of 2024.

Tampa General radiology rides out 2 hurricanes with strategic disaster preparedness

Raj Kedar, MD, chief of imaging, discusses how the hospital planned to continue operations last fall when faced with hurricanes Helene and Milton.
 

Michael J. Reardon, MD, the Allison Family Distinguished Chair in Cardiovascular Research and a professor of medicine at the DeBakey Heart and Vascular Center, Houston Methodist Hospital, explains the late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting. The data show positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).

Self-expanding TAVR valves deliver outcomes and durability comparable to surgery after 5 years

Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways. 

Society of Cardiovascular Angiography and Interventions (SCAI) President James B. Hermiller, Jr., MD, director of the transcatheter structural heart program at Ascension St. Vincent Heart Center in Indianapolis, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons that cause orthopedic injury.

SCAI pushes for better radiation protection in cath labs

Society of Cardiovascular Angiography and Interventions President James Hermiller, Jr., MD, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons.

Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, explains what he sees as the top recent trials impacting acute coronary syndrome care (ACS).

Tracking major trends and clinical research in acute coronary syndrome care

Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.

Gudrun Feuchtner, MD, MBA, HCM, assistant professor, cardiovascular imaging, Medical University Innsbruck, Department Radiology, explains how artificial intelligence-based quantitative computed tomography (AI QCT) coronary plaque features are better able to predict risk in women, according the the results of the late-breaking CONFIRM2 study at ACC 2025.

AI-based coronary plaque evaluations highlight elevated heart risks in women

“This is the perfect technique to identify high-risk patients who would benefit from intensive therapies,” imaging specialist Gudrun Feuchtner, MD, told Cardiovascular Business.

Video of Erik Rockswold explaining the administrative burdens of the MIPS program.

Radiology groups face hardships under the Medicare MIPS program

Erik Rockswold, director research and quality, Rayus Radiology, explains the administrative burdens radiology groups experience for little return from the Merit-Based Incentive Payment System.  

Video of Deepak Bhatt explaining the benefits of bentracimab in the late-breaking Phase 3 REVERSE-IT trial.

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'

Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."